Article Details
Retrieved on: 2021-06-28 11:48:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca and Sanofi's respiratory syncytial virus (RSV) drug candidate nirsevimab has performed similarly to the incumbent product Synagis in a ...
Article found on: www.fiercebiotech.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here